AstraZeneca appoints former FDA cell and gene therapy expert Laura Pashoin-Aje as Vice President and Head of Cell Therapy Regulatory Science & Strategy
Strategic Talent Acquisition
AstraZeneca recently appointed Laura Pashoin-Aje, a former FDA official, as Vice President and Head of Cell Therapy Regulatory Science & Strategy. This move is intended to strengthen its regulatory response capabilities in the rapidly expanding cell and gene therapy sector.
Core Role of Regulatory Science
Cell and gene therapies involve complex manufacturing, quality control, and stringent clinical data requirements, making regulatory science a critical success factor. Regulatory science, grounded in scientific evidence, optimizes communication with regulatory agencies and directly impacts the reduction of drug development timelines.
Laura Pashoin-Aje’s Expertise
Dr. Laura Pashoin-Aje served at the FDA for approximately 12 years, overseeing clinical evaluation of cell and gene therapies. She has acted as a bridge between regulatory guideline development and practical implementation, providing immediate operational value to AstraZeneca’s pipeline.
Market and Patient Impact
Cell and gene therapies are rapidly growing in high‑value areas such as oncology and rare diseases. Streamlined regulatory processes enable faster market entry of new drugs, improving patient access. Through this hire, AstraZeneca aims to gain an advantage over competitors in approval speed and market entry strategy.
AstraZeneca’s acquisition of regulatory expertise in cell and gene therapy is expected to accelerate new drug approvals and increase pipeline value. Job seekers targeting regulatory science roles should consider the growth potential of this field when applying.
Source: FierceBiotech (rss)
https://www.fiercebiotech.com/biotech/chutes-ladders-astrazeneca-adds-fda-cell-and-gene-veteran